Physician profile
Yaffa Weaver
NPI 1588637649
$1,279.97
in general payments reported to CMS, 2019-2025
19 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.96 · 2020: $92.77 · 2021: $305 · 2022: $65.46 · 2023: $125 · 2024: $110 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.94 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $197.30 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $181.99 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $161.50 | 2025 | Tecnis Iol |
| Lkc Technologies, INC. | $101.14 | 2025 | |
| Merz Pharmaceuticals, LLC | $93.20 | 2022-2025 | Xeomin |
| Bausch & Lomb Americas INC. | $86.55 | 2023-2025 | Miebo, Xiidra |
| Alexion Pharmaceuticals, INC. | $65.86 | 2024-2025 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $61.14 | 2020-2025 | |
| Rxsight INC | $56.55 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Astellas Pharma US INC | $54.14 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $38.98 | 2025 | Xdemvy |
| Abbvie INC. | $34.21 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $29.95 | 2022-2023 | |
| Horizon Therapeutics Plc | $28.36 | 2021-2023 | Tepezza |
| Dompe US, INC. | $22.66 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.78 | 2025 | Tepezza |
| Alcon Vision LLC | $19.07 | 2025 | Eysuvis |
| Ocular Therapeutix, INC. | $14.32 | 2024 | Dextenza |
| Ivantis, INC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaffa Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.